AbVacc, Inc. is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases using structure-guided design. AbVacc’s pipeline includes promising product candidates for prevention and treatment of bacterial and viral infections. AbVacc’s bacterial program primary focus is on staphylococcal infections, by targeting a variety of virulence factors such as toxins and critical enzymes produced by S. aureus. AbVacc’s S. aureus vaccine (IBT-V02), developed for prevention of recurrent skin and soft tissues infection, is expected to enter the clinic in 2023. AbVacc has also developed a large collection of potently neutralizing fully human and macaque-human chimeric antibodies against S. aureus virulence factors, currently under development for treatment of various S. aureus invasive diseases such as bacteremia and orthopedic infections. AbVacc’s antiviral pipeline includes unique Ebola and Marburg antibody therapeutics and vaccines for filoviruses and Nipah virus, and a strong discovery pipeline for emerging viruses. Further, AbVacc has developed a novel antibody engineering platform technology for targeting anti-toxin antibodies to the surface of bacteria, integrating toxin neutralization with effector functions.

Located in Rockville, Maryland, IBT has a close working relationship with United States Government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Cancer Institute (NCI), Department of Defense (DOD), United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and many biotechnology and pharmaceutical companies and academic laboratories.